[Eradication therapy of Helicobacter pylori--associated diseases: efficacy, safety, pharmacoeconomy].
Grinevich
V B
VB
Sablin
O A
OA
Gubonina
I V
IV
Dobrenko
V A
VA
D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D017291:Clarithromycin / Q000191:economics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy* / Q000191:economics; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000191:economics / Q000382:microbiology; D054328:Proton Pump Inhibitors; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; D009942:Organometallic Compounds; D054328:Proton Pump Inhibitors; D017291:Clarithromycin; C002791:bismuth tripotassium dicitrate